Hyperinsulinism Medication
- Author: Robert J Ferry Jr, MD; Chief Editor: Stephen Kemp, MD, PhD more...
Medication Summary
Medical therapy is the treatment of choice. Patients with hyperinsulinism often require multiple medications to maintain normoglycemia. Patients with severe hyperinsulinism may be refractory to medical therapy and may require excision of a portion of or the entire pancreas. In general, maintenance of normoglycemia should be attempted before pancreatectomy is considered. At the same time, because hypoglycemia can result in irreversible brain damage, surgical excision should not be delayed in patients with severe hypoglycemia.
Insulin secretion inhibiting agents
Class Summary
Insulin secretion may be altered by various mechanisms. Oral diazoxide inhibits pancreatic secretion of insulin, stimulates glucose release from the liver, and stimulates catecholamine release, which elevates blood glucose levels. Octreotide is a peptide with pharmacologic action similar to that of somatostatin, which inhibits insulin secretion. KATPs (ATP–sensitive potassium-dependent channels, composed of the SUR1 and Kir6.2) are inactive in diffuse disease. These channels initiate depolarization of the beta-cell membrane and opening of calcium channels. The resultant increase in intracellular calcium triggers insulin secretion. Calcium channel blockers block the activation of these calcium channels, decreasing insulin secretion. Nifedipine is the only calcium channel blocker that has been used for the treatment of hyperinsulinism in humans and appears to be clinically ineffective.
Diazoxide (Proglycem)
First-line treatment. PO diazoxide (Proglycem) opens KATP channels and inhibits insulin secretion. The IV preparation (Hyperstat) is not used in hyperinsulinism.
Octreotide (Sandostatin)
Somatostatin analogue, activates G-protein K channel. Hyperpolarization of beta cell results in inhibition of calcium influx and insulin release. Octreotide also used for acromegaly, carcinoid tumors, and VIPomas.
Nifedipine (Adalat, Procardia)
Blocks calcium channels and insulin release. Also used to treat hypertension and angina.
Dextrose and glucose release stimulators
Class Summary
Emergent blood glucose elevation requires intravenous dextrose. Glucagon enhances release of hepatic glycogen as glucose.
Dextrose (D-glucose)
IV glucose is used to elevate serum glucose levels promptly. PO glucose is rapidly absorbed from intestine and stored or used by the tissues. Parenterally injected dextrose is used in patients unable to sustain adequate PO intake. Direct PO absorption results in a rapid increase in blood glucose concentrations. Dextrose is effective in small doses, and no evidence exists that it may cause toxicity. Concentrated dextrose infusions provide higher amounts of glucose in a small volume of fluid but require central venous access for concentrations above 12.5% to reduce hyperosmolar damage to smaller peripheral blood vessels.
Glucagon
Stimulates hepatic glycogenolysis and gluconeogenesis.
Drugs inhibiting insulin effect
Class Summary
In refractory cases, cortisol and growth hormone have been used with variable rates of success to inhibit insulin effects. Both diminish the hypoglycemic effects of insulin. They may also enhance ketogenesis and increase the availability of alternative fuels.
Hydrocortisone (Hydrocortone, Cortef, Solu-Cortef)
Possesses glucocorticoid activity and weak mineralocorticoid effects. Causes peripheral insulin resistance, gluconeogenesis, and, with prolonged therapy, increased pancreatic release of glucagon (which promotes glycogenolysis).
Growth hormone, human (Genotropin, Humatrope, Nutropin)
Recombinant hGH. Some patients demonstrate reduced glucose requirement and improved glycemic control. Stimulates growth of linear bone, skeletal muscle, and organs. Stimulates erythropoietin, which increases red blood cell mass. Should not be considered an alternative to continuous SC glucagon, intermittent octreotide, or pancreatectomy.
Abdulhadi-Atwan M, Bushmann J, et al. Novel de novo mutation in sulfonylurea receptor 1 presenting as hyperinsulinism in infancy followed by overt diabetes in early adolescence. Diabetes. Jul 2008;57(7):1935-40. [Medline].
Arbizu Lostao J, Fernandez-Marmiesse A, Garrastachu Zumarran P, et al. [18F-fluoro-L-DOPA PET-CT imaging combined with genetic analysis for optimal classification and treatment in a child with severe congenital hyperinsulinism.]. An Pediatr (Barc). May 2008;68(5):481-5. [Medline].
Glaser B, Kesavan P, Heyman M, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998;338:226-30. [Medline].
Grimberg A, Ferry RJ Jr, Kelly A, et al. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes. 2001;50:322-8. [Medline].
Shah JH, Maguire DJ, Munce TB, Cotterill A. Alanine in HI: a silent mutation cries out!. Adv Exp Med Biol. 2008;614:145-50. [Medline].
Stanley CA, Baker L. The causes of neonatal hypoglycemia. N Engl J Med. Apr 15 1999;340(15):1200-1. [Medline].
Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998;338:1352-7. [Medline].
Suchi M, MacMullen CM, Thornton PS. Molecular and immunohistochemical analyses of the focal form of congenital hyperinsulinism. Mod Pathol. 2006;19:122-9. [Medline].
Thomas PM, Cote GJ, Wohllk N, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science. 1995;268:426-9. [Medline].
Hardy OT, Hernandez-Pampaloni M, Saffer JR, et al. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007;92:4706-11. [Medline].
Craver RD, Hill CB. Cure of hypoglycemic hyperinsulinism by enucleation of a focal islet cell adenomatous hyperplasia. J Pediatr Surg. 1997;32:1526-7. [Medline].
Cucchiaro G, Markowitz SD, Kaye R, et al. Blood glucose control during selective arterial stimulation and venous sampling for localization of focal hyperinsulinism lesions in anesthetized children. Anesth Analg. 2004;99:1044-8, table of contents. [Medline].
[Best Evidence] [Guideline] De Leon DD, Stanley CA. Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007;3:57-68. [Medline].
de Lonlay-Debeney P, Poggi-Travert F, Fournet JC. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med. 1999;340:1169-75. [Medline].
Ferry RJ Jr, Franklin SL, Geffner ME. Hypoglycemia. In: Kappy MS, Allen DB, Geffner ME, eds. Principles and Practice of Pediatric Endocrinology. Springfield, Ill: Charles C Thomas Publisher, Ltd; 2005:607-34.
Ferry RJ Jr, Kelly A, Grimberg A, et al. Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism. J Pediatr. 2000;137:239-46. [Medline].
Hoe FM, Thornton PS, Wanner LA. Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. J Pediatr. Feb 2006;148(2):207-12. [Medline].
Hussain K, Aynsley-Green A, Stanley CA. Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI). Pediatr Endocrinol Rev. Nov 2004;2 Suppl 1:163-7. [Medline].
Kane C, Shepherd RM, Squires PE, et al. Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nat Med. 1996;2:1344-7. [Medline].
Levitt Katz LE, Satin-Smith MS, Collett-Solberg P, et al. Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism. J Pediatr. Aug 1997;131(2):193-9. [Medline].
Lovvorn HN III, Nance ML, Ferry RJ Jr. Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. J Pediatr Surg. 1999;34:786-92; discussion 792-3. [Medline].
Palladino AA, Bennett MJ, Stanley CA. Hyperinsulinism in infancy and childhood: when an insulin level is not always enough. Clin Chem. 2008;54:256-63. [Medline].
Stanley CA. Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism. Mol Genet Metab. Apr 2004;81 Suppl 1:S45-51. [Medline].
Steinkrauss L, Lipman TH, Hendell CD. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J Pediatr Nurs. Apr 2005;20(2):109-18. [Medline].
Suchi M, Thornton PS, Adzick NS, et al. Congenital hyperinsulinism: intraoperative biopsy interpretation can direct the extent of pancreatectomy. Am J Surg Pathol. Oct 2004;28(10):1326-35. [Medline].
Cherubini V, Bagalini LS, Ianilli A, Marigliano M, Biagioni M, Carnielli V, et al. Rapid genetic analysis, imaging with 18F-DOPA-PET/CT scan and laparoscopic surgery in congenital hyperinsulinism. J Pediatr Endocrinol Metab. 2010;23:171-7. [Medline].
Print
